Cadrenal Therapeutics (CVKD) Operating Expenses (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Operating Expenses of $2.5 million for Q3 2024, little changed sequentially from $2.5 million in Q2 2024, and up 115.3% YoY from $1.1 million in Q4 2023.
Cadrenal Therapeutics (CVKD) Operating Expenses (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Operating Expenses for 3 years, with the latest figure at $2.5 million in Q3 2024.
- Quarterly Operating Expenses rose 115.3% year-over-year to $2.5 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $2.5 million (down 54.15% YoY) and the FY2023 annual result came in at $3534.0, down 91.21% from the prior year.
- Operating Expenses was little changed at $2.5 million in Q3 2024 per CVKD's latest filing, from $2.5 million in the prior quarter.
- Over five years, Operating Expenses peaked at $4.2 million in Q1 2023 and troughed at -$1.6 million in Q4 2022.
- A 3-year average of $1.3 million and a median of $1.1 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses soared 2363.18% in 2023, then slumped 58.2% in 2024.
- Over 3 years, Operating Expenses stood at -$1.6 million in 2022, then soared by 172.07% to $1.1 million in 2023, then surged by 115.3% to $2.5 million in 2024.
- According to Business Quant data, Operating Expenses over the past three periods registered $2.5 million, $2.5 million, and $1.8 million for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Cadrenal Therapeutics | 4.63 Mn | 2.23 Mn | - | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.34 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Sep 30, 2024 | 2.46 Mn |
| Jun 30, 2024 | 2.47 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 4.20 Mn |
| Dec 31, 2022 | -1.59 Mn |
| Sep 30, 2022 | 972,791.00 |
| Jun 30, 2022 | 482,347.00 |
| Mar 31, 2022 | 170,521.00 |